Top

Published in:

01-02-2019 | Cytostatic Therapy | Review

Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview

Authors: Miguel Alberto, Andreas Brandl, Pankaj Kumar Garg, Safak Gül-Klein, Mathias Dahlmann, Ulrike Stein, Beate Rau

Published in: Clinical & Experimental Metastasis | Issue 1/2019

Abstract

This manuscript aspires to portray a review of the current literature focusing on manifest peritoneal metastasis (PM) derived from gastric cancer and its treatment options. Despite the development of chemotherapy and multimodal treatment options during the last decades, mortality remains high worldwide. After refreshing important epidemiological considerations, the molecular mechanisms currently accepted through which PM occurs are revised. Palliative chemotherapy is the only recommended treatment option for patients with PM of gastric cancer according to the National Comprehensive Cancer Network guidelines, although cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy demonstrated promising results in selected patients with regional PM and localized intraabdominal tumor spread. A novel treatment named pressurized intraperitoneal aerosol chemotherapy may have a promising future in improving overall survival with an acceptable postoperative complication rate and stabilizing quality of life during treatment. Additionally, the procedure has been proved to be safe for the patient and medical personnel and a feasible, repeatable method to deter metastatic proliferation. This overview comprehensively addresses this novel and promising treatment in the context of a scientifically and clinically challenging disease.

Thomassen I, Van Gestel YR, Van Ramshorst B et al (2013) Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer 134:622–628. https://doi.org/10.1002/ijc.28373 CrossRefPubMed

Yang D, Hendifar A, Lenz C et al (2011) Survival of metastatic gastric cancer: significance of age, sex and race/ethnicity. J Gastrointest Oncol 2:77–84. https://doi.org/10.3978/j.issn.2078-6891.2010.025 CrossRefPubMedPubMedCentral

van Baal JOAM, Van de Vijver KK, Nieuwland R et al (2017) The histophysiology and pathophysiology of the peritoneum. Tissue Cell 49:95–105. https://doi.org/10.1016/j.tice.2016.11.004 CrossRefPubMed

American Cancer Society (2015) Global cancer facts & figs, 3rd edn. American Cancer Society, Atlanta

Balakrishnan M, George R, Sharma A, Graham DY (2017) Changing trends in stomach cancer throughout the world. Curr Gastroenterol Rep 19:36. https://doi.org/10.1007/s11894-017-0575-8 CrossRefPubMedPubMedCentral

Lu M, Yang Z, Feng Q et al (2016) The characteristics and prognostic value of signet ring cell histology in gastric cancer: a retrospective cohort study of 2199 consecutive patients. Medicine 95(27):e4052. https://doi.org/10.1097/MD.0000000000004052 CrossRefPubMedPubMedCentral

Sugarbaker PH (2018) Gastric cancer: prevention and treatment of peritoneal metastases. J Cancer Metastasis Treat 4:7. https://doi.org/10.20517/2394-4722.2017.67 CrossRef

Sugarbaker PH, Yonemura Y (2000) Clinical pathway for the management of resectable gastric cancer with peritoneal seeding: best palliation with a ray of hope for cure. Oncology 58(2):96–107CrossRefPubMed

Gretschel S, Siegel R, Estévez-Schwarz L et al (2006) Surgical strategies for gastric cancer with synchronous peritoneal carcinomatosis. Br J Surg 93:1530–1535. https://doi.org/10.1002/bjs.5513 CrossRefPubMed

10.

Valastyan S, Weinberg RA (2011) Review tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292. https://doi.org/10.1016/j.cell.2011.09.024 CrossRefPubMedPubMedCentral

11.

Pachmayr E, Treese C, Stein U (2017) Underlying mechanisms for distant metastasis-molecular biology. Visc Med 33(1):11–20. https://doi.org/10.1159/000454696 CrossRefPubMedPubMedCentral

12.

Takeichi M (1993) Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 5:806–811. https://doi.org/10.1016/0955-0674(93)90029-P CrossRefPubMed

13.

Peng Z, Wang C, Fang E et al (2014) Role of epithelial-mesenchymal transition in gastric cancer initiation and progression. World J Gastroenterol 20:5403–5410. https://doi.org/10.3748/wjg.v20.i18.5403 CrossRefPubMedPubMedCentral

14.

Chang M-C, Jeng J-H (2011) Tumor Cell-Induced Platelet Aggregation. In: Schwab M (ed) Encyclopedia of cancer. Springer, Berlin, p 3793–3795CrossRef

15.

Yutaka Y, Yoshio E, Tohru O, Takuma S (2006) Recent advances in the treatment of peritoneal dissemination of gastrointestinal cancers by nucleoside antimetabolites. Cancer Sci 98:11–18. https://doi.org/10.1111/j.1349-7006.2006.00350.x CrossRef

16.

Kanda M, Kodera Y (2016) Molecular mechanisms of peritoneal dissemination in gastric cancer. 22:6829–6840. https://doi.org/10.3748/wjg.v22.i30.6829

17.

Cheng T, Wu M, Lin J, Lin M (2012) Annexin A1 is associated with gastric cancer survival and promotes gastric cancer cell invasiveness through the formyl peptide receptor/extracellular signal-regulated kinase/integrin beta-1-binding protein 1 pathway. Cancer 118(23):5757–5767. https://doi.org/10.1002/cncr.27565 CrossRefPubMed

18.

Singh J, Sharma A, Ahuja N (2017) Genomics of peritoneal surface malignancies. J Perit. https://doi.org/10.4081/joper.2017.62 CrossRef

19.

Liu J, Geng X, Li Y (2016) Milky spots: omental functional units and hotbeds for peritoneal cancer metastasis. Tumor Biol 5715–5726. https://doi.org/10.1007/s13277-016-4887-3

20.

Liebermann-Meffert D, White H, Vaubel E (1983) The greater OMENTUM. Springer, BerlinCrossRef

21.

Miao ZF, Wang ZN, Zhao TT et al (2014) Peritoneal milky spots serve as a hypoxic niche and favor gastric cancer stem/progenitor cell peritoneal dissemination through hypoxia-inducible factor 1α. Stem Cells 32:3062–3074. https://doi.org/10.1002/stem.1816 CrossRefPubMedPubMedCentral

22.

Quail DF, Joyce JA (2013) Microenvironmental regulation of tumor progression and metastasis. Nat Med 19:1423–1437. https://doi.org/10.1038/nm.3394 CrossRefPubMedPubMedCentral

23.

Yan Y, Wang L-F, Wang R-F (2015) Role of cancer-associated fibroblasts in invasion and metastasis of gastric cancer. World J Gastroenterol 21:9717. https://doi.org/10.3748/wjg.v21.i33.9717 CrossRefPubMedPubMedCentral

24.

Mura G, Verdelli B (2016) The features of peritoneal metastases from gastric cancer. J Cancer Metastasis Treat 2:365. https://doi.org/10.20517/2394-4722.2016.19 CrossRef

25.

Cao L, Hu X, Zhang J et al (2014) The role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spots. J Transl Med 12:267. https://doi.org/10.1186/s12967-014-0267-1 CrossRefPubMedPubMedCentral

26.

Chen G, Chen SM, Wang X et al (2012) Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem 287:12132–12141. https://doi.org/10.1074/jbc.M111.302299 CrossRefPubMedPubMedCentral

27.

Zhang LL, Liu J, Lei S et al (2014) PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression. Cell Signal 26:1011–1020. https://doi.org/10.1016/j.cellsig.2014.01.025 CrossRefPubMed

28.

Takatsuki H, Komatsu S, Sano R et al (2004) Adhesion of gastric carcinoma cells to peritoneum mediated by α3β1 integrin (VLA-3). Cancer Res 64:6065–6070. https://doi.org/10.1158/0008-5472.CAN-04-0321 CrossRefPubMed

29.

Nishimori H, Yasoshima T, Denno R et al (2000) A novel experimental mouse model of peritoneal dissemination of human gastric cancer cells: different mechanisms in peritoneal dissemination and hematogenous metastasis. Jpn J Cancer Res 91:715–722. https://doi.org/10.1111/j.1349-7006.2000.tb01004.x CrossRefPubMedPubMedCentral

30.

Yonemura Y, Endou Y, Fujita H et al (2000) Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer. Gastric Cancer 3:63–70CrossRefPubMed

31.

Chen C-N, Chang C-C, Lai H-S et al (2015) Connective tissue growth factor inhibits gastric cancer peritoneal metastasis by blocking integrin α3β1-dependent adhesion. Gastric Cancer 18:504–515. https://doi.org/10.1007/s10120-014-0400-0 CrossRefPubMed

32.

Saito Y, Sekine W, Sano R et al (2010) Potentiation of cell invasion and matrix metalloproteinase production by alpha3beta1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. Clin Exp Metastasis 27:197–205. https://doi.org/10.1007/s10585-010-9314-3 CrossRefPubMed

33.

Li S-G, Ye Z-Y, Zhao Z-S et al (2008) Correlation of integrin β3 mRNA and vascular endothelial growth factor protein expression profiles with the clinicopathological features and prognosis of gastric carcinoma. World J Gastroenterol 14:421. https://doi.org/10.3748/wjg.14.421 CrossRefPubMedPubMedCentral

34.

Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH (2003) Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread. Cancer Metastasis Rev 22:465–472. https://doi.org/10.1023/A:1023791229361 CrossRefPubMed

35.

Takebayashi K, Murata S, Yamamoto H et al (2014) Surgery-induced peritoneal cancer cells in patients who have undergone curative gastrectomy for gastric cancer. Ann Surg Oncol 21:1991–1997. https://doi.org/10.1245/s10434-014-3525-9 CrossRefPubMed

36.

Yang S, Feng R, Pan ZC et al (2015) A comparison of intravenous plus intraperitoneal chemotherapy with intravenous chemotherapy alone for the treatment of gastric cancer: a meta-analysis. Sci Rep 5:1–12. https://doi.org/10.1038/srep12538 CrossRef

37.

Ishigami H, Fujiwara Y, Fukushima R et al (2018) Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 36:1922–1929. https://doi.org/10.1200/JCO.2018.77.8613 CrossRefPubMed

38.

Canbay E, Mizumoto A, Ichinose M et al (2014) Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 21:1147–1152. https://doi.org/10.1245/s10434-013-3443-2 CrossRefPubMed

39.

Yang X-J, Huang C-Q, Suo T et al (2011) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 18:1575–1581. https://doi.org/10.1245/s10434-011-1631-5 CrossRefPubMedPubMedCentral

40.

Rudloff UDO, Langan RC, Mullinax JE et al (2014) Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial. J Surg Oncol, 110(3):275–284. https://doi.org/10.1002/jso.23633 CrossRefPubMedPubMedCentral

41.

Glehen O, Gilly FN, Arvieux C et al (2010) Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol 17:2370–2377. https://doi.org/10.1245/s10434-010-1039-7 CrossRefPubMed

42.

Magge D, Zenati M, Mavanur A et al (2014) Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol 21:1448–1455. https://doi.org/10.1245/s10434-013-3327-5 CrossRefPubMed

43.

Harmon RL, Sugarbaker PH (2005) Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer. Int Semin Surg Oncol 2:3. https://doi.org/10.1186/1477-7800-2-3 CrossRefPubMedPubMedCentral

44.

Lagast N, Carlier C, Ceelen WP (2018) Pharmacokinetics and tissue transport of intraperitoneal chemotherapy. Surg Oncol Clin N Am 27:477–494. https://doi.org/10.1016/j.soc.2018.02.003 CrossRefPubMed

45.

Carlier C, Mathys A, De Jaeghere E et al (2017) Tumour tissue transport after intraperitoneal anticancer drug delivery. Int J Hyperth 33:534–542. https://doi.org/10.1080/02656736.2017.1312563 CrossRef

46.

Jacquet P, Stuart OA, Chang D, Sugarbaker PH (1996) Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration. Anticancer Drugs 7:596–603CrossRefPubMed

47.

Esquis P, Consolo D, Magnin G et al (2006) High intra-abdominal pressure enhances the penetration and antitumor effect of intraperitoneal cisplatin on experimental peritoneal carcinomatosis. Ann Surg 244:106–112. https://doi.org/10.1097/01.sla.0000218089.61635.5f CrossRefPubMedPubMedCentral

48.

Facy O, Al Samman S, Magnin G et al (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256:1084–1088. https://doi.org/10.1097/SLA.0b013e3182582b38 CrossRefPubMed

49.

Kusamura S, Luca F, Baratti D et al (2018) Phase II randomized study on tissue distribution of cisplatin according to different levels of intra abdominal pressure during HIPEC: preliminary results. NCT02949791. Eur J Surg Oncol 44:e7. https://doi.org/10.1016/j.ejso.2018.07.029 CrossRef

50.

Tempfer CB, Hilal Z, Dogan A et al (2018) Concentrations of cisplatin and doxorubicin in ascites and peritoneal tumor nodules before and after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in patients with peritoneal metastasis. Eur J Surg Oncol 44:1112–1117. https://doi.org/10.1016/j.ejso.2018.04.020 CrossRefPubMed

51.

Cho H-K, Lush RM, Bartlett DL et al (1999) Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 39:394–401. https://doi.org/10.1177/00912709922007967 CrossRefPubMed

52.

Khosrawipour V, Khosrawipour T, Kern AJP et al (2016) Distribution pattern and penetration depth of doxorubicin after pressurized intraperitoneal aerosol chemotherapy (PIPAC) in a postmortem swine model. J Cancer Res Clin Oncol 142:2275–2280. https://doi.org/10.1007/s00432-016-2234-0 CrossRefPubMed

53.

Coccolini F, Acocella F, Morosi L et al (2017) High penetration of paclitaxel in abdominal wall of rabbits after hyperthermic intraperitoneal administration of Nab-Paclitaxel compared to standard paclitaxel formulation. Pharm Res 34:1180–1186. https://doi.org/10.1007/s11095-017-2132-4 CrossRefPubMed

54.

Jung DH, Son SY, Oo AM et al (2016) Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc 30:4258–4264. https://doi.org/10.1007/s00464-015-4738-0 CrossRef

55.

Galluzzi L, Vitale I, Michels J et al (2014) Systems biology of cisplatin resistance: past, present and future. Cell Death Dis 5:e1257–e1218. https://doi.org/10.1038/cddis.2013.428 CrossRefPubMedPubMedCentral

56.

Barenholz Y (2012) Doxil®—the first FDA-approved nano-drug: lessons learned. J Control Release 160:117–134. https://doi.org/10.1016/j.jconrel.2012.03.020 CrossRefPubMed

57.

Franco Y, Vaidya T, Ait-Oudhia S (2018) Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer Targets Ther 10:131–141. https://doi.org/10.2147/BCTT.S170239 CrossRef

58.

Bharadwaj R, Yu H (2004) The spindle checkpoint, aneuploidy, and cancer. Oncogene 23:2016

59.

Brito DA, Yang Z, Rieder CL (2008) Microtubules do not promote mitotic slippage when the spindle assembly checkpoint cannot be satisfied. J Cell Biol 182:623 LP–L629CrossRef

60.

Solaß W, Hetzel A, Nadiradze G et al (2012) Description of a novel approach for intraperitoneal drug delivery and the related device. Surg Endosc 26:1849–1855. https://doi.org/10.1007/s00464-012-2148-0 CrossRefPubMed

61.

Solass W, Kerb R, Mürdter T et al (2014) Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol 21:553–559. https://doi.org/10.1245/s10434-013-3213-1 CrossRefPubMed

62.

Jacquet P, Sugarbaker PH (1996) Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 82:359–374CrossRefPubMed

63.

Ametsbichler P, Böhlandt A, Nowak D, Schierl R (2018) Occupational exposure to cisplatin/oxaliplatin during pressurized intraperitoneal aerosol chemotherapy (PIPAC)?. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2018.05.020 CrossRefPubMed

64.

Solaß W, Giger-Pabst U, Zieren J, Reymond MA (2013) Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol 20:3504–3511. https://doi.org/10.1245/s10434-013-3039-x CrossRefPubMedPubMedCentral

65.

Weinreich J, Struller F, Sautkin I et al (2018) Chemosensitivity of various peritoneal cancer cell lines to HIPEC and PIPAC: comparison of an experimental duplex drug to standard drug regimens in vitro. Investig New Drugs. https://doi.org/10.1007/s10637-018-0641-6 CrossRef

66.

Tempfer CB, Giger-Pabst U, Seebacher V et al (2018) A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. Gynecol Oncol 150:23–30. https://doi.org/10.1016/j.ygyno.2018.05.001 CrossRefPubMed

67.

Sleeman JP (2017) PIPAC puts pressure on peritoneal metastases from pancreatic cancer. Clin Exp Metastasis 34:291–293. https://doi.org/10.1007/s10585-017-9851-0 CrossRefPubMed

68.

Struller F, Horvath P, Solass W et al (2017) Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis (PIPAC-GA1). J Clin Oncol 35:99. https://doi.org/10.1200/JCO.2017.35.4_suppl.99 CrossRef

69.

Nadiradze G, Giger-Pabst U, Zieren J et al (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with low-dose cisplatin and doxorubicin in gastric peritoneal metastasis. J Gastrointest Surg 20:367–373. https://doi.org/10.1007/s11605-015-2995-9 CrossRefPubMed

70.

Alyami M, Gagniere J, Sgarbura O et al (2017) Multicentric initial experience with the use of the pressurized intraperitoneal aerosol chemotherapy (PIPAC) in the management of unresectable peritoneal carcinomatosis. Eur J Surg Oncol 43:2178–2183. https://doi.org/10.1016/j.ejso.2017.09.010 CrossRefPubMed

71.

Odendahl K, Solass W, Demtröder C et al (2015) Quality of life of patients with end-stage peritoneal metastasis treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC). Eur J Surg Oncol 41:1379–1385. https://doi.org/10.1016/j.ejso.2015.06.001 CrossRefPubMed

72.

Girshally R, Demtröder C, Albayrak N et al (2016) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) as a neoadjuvant therapy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 14:253. https://doi.org/10.1186/s12957-016-1008-0 CrossRefPubMedPubMedCentral

73.

Nowacki M, Grzanka D, Zegarski W (2018) Pressurized intraperitoneal aerosol chemotheprapy after misdiagnosed gastric cancer: case report and review of the literature. World J Gastroenterol 24:2130–2136. https://doi.org/10.3748/wjg.v24.i19.2130 CrossRefPubMedPubMedCentral

74.

Chan DL, Sjoquist KM, Goldstein D et al (2017) The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: a systematic review and meta-analysis. PLoS ONE 12:e0172307. https://doi.org/10.1371/journal.pone.0172307 CrossRefPubMedPubMedCentral

75.

Thuss-Patience PC, Kretzschmar A, Dogan Y et al (2011) Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer 105:505–512. https://doi.org/10.1038/bjc.2011.278 CrossRefPubMedPubMedCentral

76.

Khomiakov V, Ryabov A, Bolotina LV et al (2017) Bidirectional chemotherapy in gastric cancer (GC) with peritoneal carcinomatosis (PC) combining intravenous chemotherapy with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase. J Clin Oncol 35:e15532–e15532. https://doi.org/10.1200/JCO.2017.35.15_suppl.e15532 CrossRef

77.

Alyami M, Bonnot PE, Villeneuve L et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for nonresectable peritoneal carcinomatosis from gastric cancer. J Clin Oncol 36:149. https://doi.org/10.1200/JCO.2018.36.4_suppl.149 CrossRef

78.

Tempfer CB, Rezniczek GA, Ende P (2015) Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin in women with peritoneal carcinomatosis: a cohort study. Anticancer Res 35:6723–6730PubMed

79.

Khomyakov V, Ryabov A, Ivanov A et al (2016) Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatis and Doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2). 1:159–166. https://doi.org/10.1515/pap-2016-0017

80.

Blanco A, Giger-Pabst U, Solass W et al (2013) Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol 20:2311–2316. https://doi.org/10.1245/s10434-012-2840-2 CrossRefPubMedPubMedCentral

81.

Ndaw S, Hanser O, Kenepekian V et al (2018) Occupational exposure to platinum drugs during intraperitoneal chemotherapy. Biomonitoring and surface contamination. Toxicol Lett. https://doi.org/10.1016/j.toxlet.2018.05.031 CrossRefPubMed

82.

Jansen-Winkeln B, Thieme R, Haase L et al (2018) Perioperative sicherheit der intraperitonealen aerosolchemotherapie. Der Chir. https://doi.org/10.1007/s00104-018-0667-5 CrossRef

83.

Graversen M, Detlefsen S, Pfeiffer P et al (2018) Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey. Clin Exp Metastasis 35:103–108. https://doi.org/10.1007/s10585-018-9895-9 CrossRefPubMed

84.

Nowacki M, Alyami M, Villeneuve L et al (2018) Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2018.02.014 CrossRefPubMed

85.

Dumont F, Senellart H, Pein F et al (2018) Phase I/II study of oxaliplatin dose escalation via a laparoscopic approach using pressurized aerosol intraperitoneal chemotherapy (PIPOX trial) for nonresectable peritoneal metastases of digestive cancers (stomach, small bowel and colorectal): rationale and design. Pleura Perit. https://doi.org/10.1515/pp-2018-0120 CrossRef

86.

Goetze TO, Al-Batran SE, Pabst U et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in combination with standard of care chemotherapy in primarily untreated chemo naive upper gi-adenocarcinomas with peritoneal seeding—A phase II/III trial of the AIO/CAOGI/ACO. Pleura Perit. https://doi.org/10.1515/pp-2018-0113 CrossRef

87.

Eveno C, Jouvin I, Pocard M (2018) PIPAC EstoK 01: pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in gastric peritoneal metastasis : a randomized and multicenter phase II study. Pleura Perit 1–7. https://doi.org/10.1515/pap-2018-0116

88.

Minnaert A-K, Dakwar GR, Benito JM et al (2017) High-pressure nebulization as application route for the peritoneal administration of sirna complexes. Macromol Biosci 17:1700024. https://doi.org/10.1002/mabi.201700024 CrossRef

89.

Ceelen WP, Van de Sande L (2018) PIPAC Nab-pac for stomach, pancreas, breast and ovarian cancer (PIPAC-nabpac). https://clinicaltrials.gov/ct2/show/NCT03304210

90.

Mortensen MB (2017) Treatment of Peritoneal carcinomatosis with pressurized intraperitoneal aerosol chemotherapy—(PIPAC-OPC2). https://clinicaltrials.gov/ct2/show/NCT03287375

91.

So J, Guowei K (2017) Pressurized Intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin in patients with peritoneal carcinomatosis (PIPAC). https://clinicaltrials.gov/ct2/show/NCT03172416

Title: Pressurized intraperitoneal aerosol chemotherapy and its effect on gastric-cancer-derived peritoneal metastases: an overview
Authors: Miguel Alberto
Andreas Brandl
Pankaj Kumar Garg
Safak Gül-Klein
Mathias Dahlmann
Ulrike Stein
Beate Rau
Publication date: 01-02-2019
Publisher: Springer Netherlands
Keywords: Cytostatic Therapy
Gastric Cancer
Gastric Cancer
Metastasis
Published in: Clinical & Experimental Metastasis / Issue 1/2019
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-09955-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases

Hepatic arterial infusion of irinotecan and EmboCept® S results in high tumor concentration of SN-38 in a rat model of colorectal liver metastases

Metastasis in the wild: investigating metastasis in non-laboratory animals

Sema4D expression and secretion are increased by HIF-1α and inhibit osteogenesis in bone metastases of lung cancer

Correction to: The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity

Keynote webinar | Spotlight on antibody–drug conjugates in cancer